Skip to main content


Fig. 3 | BMC Cancer

Fig. 3

From: Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma

Fig. 3

Increased hepcidin and GDF-15 serum levels were associated with patient’s outcome in UUTUC. For analysis of relapse patients were divided into the two subgroups of (a) patients with relapse and (b) patients without relapse. (a) Serum hepcidin levels (***p ≤ 0.0001) and (b) serum GDF-15 levels (***p ≤ 0.0001, *p = 0.03) of UUTUC patients were compared to control patients. (c) For survival analysis patients were assigned to two groups according to their serum hepcidin and GDF-15 levels, respectively. Patients with serum hepcidin levels below 40.5 ng/ml had a higher survival than patients with serum hepcidin levels above 40.5 ng/ml (Log-Rank **p = 0.003). Ticks indicate right-censoring. (d) There was a trend towards higher survival for patients with GDF-15 serum levels above 1200 pg/ml (Log-Rank p = 0.076)

Back to article page